Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1080/1744666X.2021.1847084 http://scihub22266oqcxt.onion/10.1080/1744666X.2021.1847084 33146561!7879704!33146561     free     free     free Warning: file_get_contents(https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&id=33146561&cmd=llinks): Failed to open stream: HTTP request failed! HTTP/1.1 429 Too Many Requests in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 215       Expert+Rev+Clin+Immunol 2020 ; 16 (12): 1185-1204 Nephropedia Template TP {{tp|p=33146561|t=2020. Coronavirus disease 2019: investigational therapies in the prevention and treatment of hyperinflammation |pdf=|usr=}}{{33146561}} gab.com Text Coronavirus disease 2019: investigational therapies in the prevention and treatment of hyperinflammation JO: Expert Rev Clin Immunol http://www.kidney.de/pget.php?&tw=1&pmid=33146561 #FOAvip Introduction: The mortality of coronavirus disease 2019 (COVID-19) is frequently driven by an injurious immune response characterized by the development of acute respiratory distress syndrome (ARDS), endotheliitis, coagulopathy, and multi-organ failure. This spectrum of hyperinflammation in COVID-19 is commonly referred to as cytokine storm syndrome (CSS). Areas covered: Medline and Google Scholar were searched up until 15th of August 2020 for relevant literature. Evidence supports a role of dysregulated immune responses in the immunopathogenesis of severe COVID-19. CSS associated with SARS-CoV-2 shows similarities to the exuberant cytokine production in some patients with viral infection (e.g.SARS-CoV-1) and may be confused with other syndromes of hyperinflammation like the cytokine release syndrome (CRS) in CAR-T cell therapy. Interleukin (IL)-6, IL-8, and tumor necrosis factor-alpha have emerged as predictors of COVID-19 severity and in-hospital mortality. Expert opinion: Despite similarities, COVID-19-CSS appears to be distinct from HLH, MAS, and CRS, and the application of HLH diagnostic scores and criteria to COVID-19 is not supported by emerging data. While immunosuppressive therapy with glucocorticoids has shown a mortality benefit, cytokine inhibitors may hold promise as 'rescue therapies' in severe COVID-19. Given the arguably limited benefit in advanced disease, strategies to prevent the development of COVID-19-CSS are needed. Twit Text FOAVip Coronavirus disease 2019: investigational therapies in the prevention and treatment of hyperinflammation ????Expert Rev Clin Immunol http://www.kidney.de/pget.php?&tw=1&pmid=33146561 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=33146561 #FOAvip English Wikipedia <ref>{{Cite pmid|33146561}}</ref> Coronavirus disease 2019: investigational therapies in the prevention and treatment of hyperinflammation #MMPMID33146561 Amigues I; Pearlman AH; Patel A; Reid P; Robinson PC; Sinha R; Kim AH; Youngstein T; Jayatilleke A; Konig M Expert Rev Clin Immunol 2020[Dec]; 16 (12): 1185-1204 PMID33146561show ga Introduction: The mortality of coronavirus disease 2019 (COVID-19) is frequently driven by an injurious immune response characterized by the development of acute respiratory distress syndrome (ARDS), endotheliitis, coagulopathy, and multi-organ failure. This spectrum of hyperinflammation in COVID-19 is commonly referred to as cytokine storm syndrome (CSS). Areas covered: Medline and Google Scholar were searched up until 15th of August 2020 for relevant literature. Evidence supports a role of dysregulated immune responses in the immunopathogenesis of severe COVID-19. CSS associated with SARS-CoV-2 shows similarities to the exuberant cytokine production in some patients with viral infection (e.g.SARS-CoV-1) and may be confused with other syndromes of hyperinflammation like the cytokine release syndrome (CRS) in CAR-T cell therapy. Interleukin (IL)-6, IL-8, and tumor necrosis factor-alpha have emerged as predictors of COVID-19 severity and in-hospital mortality. Expert opinion: Despite similarities, COVID-19-CSS appears to be distinct from HLH, MAS, and CRS, and the application of HLH diagnostic scores and criteria to COVID-19 is not supported by emerging data. While immunosuppressive therapy with glucocorticoids has shown a mortality benefit, cytokine inhibitors may hold promise as 'rescue therapies' in severe COVID-19. Given the arguably limited benefit in advanced disease, strategies to prevent the development of COVID-19-CSS are needed. |*COVID-19/blood/mortality/prevention & control/therapy[MESH] |*Cytokine Release Syndrome/blood/mortality/prevention & control/therapy[MESH] |*Therapies, Investigational[MESH] |Cytokines/*blood[MESH] |Humans[MESH]Coronavirus disease 2019: investigational therapies in the prevention (epmc).pdf DeepDyve Pubget Overpricing